<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle>SBIR Phase II:  Endoscopic injection device for submucosal esophageal injection of bulking agents in the treatment of gastroesophageal reflux disease</AwardTitle>
<AGENCY>NSF</AGENCY>
<AwardEffectiveDate>08/15/2020</AwardEffectiveDate>
<AwardExpirationDate>07/31/2022</AwardExpirationDate>
<AwardTotalIntnAmount>750000.00</AwardTotalIntnAmount>
<AwardAmount>0</AwardAmount>
<AwardInstrument>
<Value>Standard Grant</Value>
</AwardInstrument>
<Organization>
<Code>07070000</Code>
<Directorate>
<Abbreviation>ENG</Abbreviation>
<LongName>Directorate For Engineering</LongName>
</Directorate>
<Division>
<Abbreviation>IIP</Abbreviation>
<LongName>Div Of Industrial Innovation &amp; Partnersh</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>Henry Ahn</SignBlockName>
<PO_EMAI>hahn@nsf.gov</PO_EMAI>
<PO_PHON>7032927069</PO_PHON>
</ProgramOfficer>
<AbstractNarration>The broader/commercial impact of this SBIR Phase II project proposes to develop a minimally-invasive device for treating gastroesophageal reflux disease (GERD).  GERD is the most common gastrointestinal diagnosis in the US, afflicting ~26% of adult Americans (&gt;60 million people), undermining their sleep, productivity, and quality of life, and leading to other gastrointestinal diseases. Approximately one-third of GERD patients continue to suffer from symptoms despite treatment; moreover, long-term use of currently prescribed drugs has side effects and risks. Current surgical solutions are invasive, costly and carry significant risk. The proposed injection system offers a less invasive and costly treatment for GERD by safely injecting a treatment into the base of the esophagus, reducing healthcare costs, improving the quality of life for patients, and potentially reducing the incidence of other gastrointestinal diseases. &lt;br/&gt;&lt;br/&gt;This SBIR Phase II project will develop an endoscopic injection system for consistent multiple injections of bulking agent into the submucosal tissue plane in the lower esophagus. This technology includes a novel system controlling injection depth and directing a needle tip to the desired submucosal tissue. This project will optimize the design of the needle and associated guidance system for injection of viscous solutions, particularly a bulking agent creating submucosal tissue bulging at the lower esophagus and ultimately preventing gastroesophageal reflux. This will be the first system to use a dual lumen injection needle with the assistance of a saline pilot injection.  The project will further explore the design space of the final manifold housing with rapid iterative 3D-printing prototyping.&lt;br/&gt;&lt;br/&gt;This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.</AbstractNarration>
<MinAmdLetterDate>08/05/2020</MinAmdLetterDate>
<MaxAmdLetterDate>04/20/2021</MaxAmdLetterDate>
<ARRAAmount/>
<TRAN_TYPE>Grant</TRAN_TYPE>
<CFDA_NUM>47.041</CFDA_NUM>
<NSF_PAR_USE_FLAG>1</NSF_PAR_USE_FLAG>
<FUND_AGCY_CODE>4900</FUND_AGCY_CODE>
<AWDG_AGCY_CODE>4900</AWDG_AGCY_CODE>
<AwardID>1949263</AwardID>
<Investigator>
<FirstName>Juliana</FirstName>
<LastName>Elstad</LastName>
<PI_MID_INIT/>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Juliana Elstad</PI_FULL_NAME>
<EmailAddress>jelstad@impleomedical.com</EmailAddress>
<PI_PHON>6128507282</PI_PHON>
<NSF_ID>000738271</NSF_ID>
<StartDate>08/05/2020</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>Impleo Medical, Inc.</Name>
<CityName>St. Paul</CityName>
<CountyName/>
<ZipCode>551105959</ZipCode>
<PhoneNumber>6128507282</PhoneNumber>
<StreetAddress>1290 Hammond Rd</StreetAddress>
<StreetAddress2/>
<CountryName>United States</CountryName>
<StateName>Minnesota</StateName>
<StateCode>MN</StateCode>
<CONGRESSDISTRICT>04</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_ORG>MN04</CONGRESS_DISTRICT_ORG>
<ORG_DUNS_NUM>080176836</ORG_DUNS_NUM>
<ORG_LGL_BUS_NAME>IMPLEO MEDICAL, INC.</ORG_LGL_BUS_NAME>
<ORG_PRNT_DUNS_NUM/>
</Institution>
<Performance_Institution>
<Name><![CDATA[Impleo Medical]]></Name>
<CityName>St. Paul</CityName>
<CountyName/>
<StateCode>MN</StateCode>
<ZipCode>551105959</ZipCode>
<StreetAddress><![CDATA[1290 Hammond Road]]></StreetAddress>
<CountryCode>US</CountryCode>
<CountryName>United States</CountryName>
<StateName>Minnesota</StateName>
<CountryFlag>1</CountryFlag>
<CONGRESSDISTRICT>04</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_PERF>MN04</CONGRESS_DISTRICT_PERF>
</Performance_Institution>
<ProgramElement>
<Code>5373</Code>
<Text>SBIR Phase II</Text>
</ProgramElement>
<ProgramReference>
<Code>5345</Code>
<Text>BIOMEDICAL ENGINEERING</Text>
</ProgramReference>
<Appropriation>
<Code>0120</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<FUND_OBLG>2020~750000</FUND_OBLG>
</Award>
</rootTag>
